David Roman
Stock Analyst at Goldman Sachs
(2.08)
# 3,133
Out of 5,182 analysts
80
Total ratings
41.3%
Success rate
-3.34%
Average return
Main Sectors:
Stocks Rated by David Roman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BSX Boston Scientific | Maintains: Buy | $87 → $84 | $59.95 | +40.12% | 3 | Apr 23, 2026 | |
| BDX Becton, Dickinson and Company | Reinstates: Neutral | $167 | $150.22 | +11.17% | 2 | Apr 10, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $28 → $25 | $19.82 | +26.14% | 3 | Apr 9, 2026 | |
| SYK Stryker | Maintains: Neutral | $403 → $357 | $329.01 | +8.51% | 3 | Apr 9, 2026 | |
| OMDA Omada Health | Maintains: Buy | $26 → $23 | $14.72 | +56.25% | 2 | Apr 9, 2026 | |
| KMTS Kestra Medical Technologies | Maintains: Neutral | $22 → $17 | $22.23 | -23.53% | 4 | Apr 9, 2026 | |
| IRTC iRhythm Holdings | Maintains: Neutral | $184 → $147 | $125.96 | +16.70% | 5 | Apr 9, 2026 | |
| ISRG Intuitive Surgical | Maintains: Buy | $714 → $609 | $470.99 | +29.30% | 2 | Apr 9, 2026 | |
| PODD Insulet | Maintains: Buy | $326 → $277 | $188.31 | +47.10% | 3 | Apr 9, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Buy | $97 → $81 | $70.48 | +14.93% | 4 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $28 | $24.66 | +13.54% | 6 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $17 | $9.86 | +72.41% | 2 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $20 | $10.65 | +87.79% | 4 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $121 | $92.80 | +30.39% | 3 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $21 → $17 | $18.49 | -8.06% | 5 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $95 | $83.46 | +13.83% | 5 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $49 | $45.23 | +8.34% | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $89 | $83.47 | +6.63% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $64 → $71 | $64.34 | +10.35% | 2 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $81 → $111 | $82.92 | +33.86% | 2 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $15.88 | +0.76% | 1 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $103 | $122.07 | -15.62% | 1 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $13.53 | +47.82% | 1 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $104 | $92.59 | +12.32% | 2 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $10 | $5.85 | +70.94% | 4 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $63 → $71 | $69.78 | +1.75% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $55 | $63.41 | -13.26% | 2 | Mar 3, 2025 |
Boston Scientific
Apr 23, 2026
Maintains: Buy
Price Target: $87 → $84
Current: $59.95
Upside: +40.12%
Becton, Dickinson and Company
Apr 10, 2026
Reinstates: Neutral
Price Target: $167
Current: $150.22
Upside: +11.17%
Tandem Diabetes Care
Apr 9, 2026
Maintains: Neutral
Price Target: $28 → $25
Current: $19.82
Upside: +26.14%
Stryker
Apr 9, 2026
Maintains: Neutral
Price Target: $403 → $357
Current: $329.01
Upside: +8.51%
Omada Health
Apr 9, 2026
Maintains: Buy
Price Target: $26 → $23
Current: $14.72
Upside: +56.25%
Kestra Medical Technologies
Apr 9, 2026
Maintains: Neutral
Price Target: $22 → $17
Current: $22.23
Upside: -23.53%
iRhythm Holdings
Apr 9, 2026
Maintains: Neutral
Price Target: $184 → $147
Current: $125.96
Upside: +16.70%
Intuitive Surgical
Apr 9, 2026
Maintains: Buy
Price Target: $714 → $609
Current: $470.99
Upside: +29.30%
Insulet
Apr 9, 2026
Maintains: Buy
Price Target: $326 → $277
Current: $188.31
Upside: +47.10%
GE HealthCare Technologies
Apr 9, 2026
Maintains: Buy
Price Target: $97 → $81
Current: $70.48
Upside: +14.93%
Apr 9, 2026
Maintains: Neutral
Price Target: $34 → $28
Current: $24.66
Upside: +13.54%
Apr 9, 2026
Maintains: Buy
Price Target: $19 → $17
Current: $9.86
Upside: +72.41%
Apr 9, 2026
Maintains: Buy
Price Target: $23 → $20
Current: $10.65
Upside: +87.79%
Apr 9, 2026
Maintains: Buy
Price Target: $140 → $121
Current: $92.80
Upside: +30.39%
Feb 17, 2026
Maintains: Neutral
Price Target: $21 → $17
Current: $18.49
Upside: -8.06%
Feb 11, 2026
Maintains: Buy
Price Target: $108 → $95
Current: $83.46
Upside: +13.83%
Jan 12, 2026
Initiates: Buy
Price Target: $49
Current: $45.23
Upside: +8.34%
Jan 9, 2026
Downgrades: Sell
Price Target: $89
Current: $83.47
Upside: +6.63%
Dec 8, 2025
Maintains: Sell
Price Target: $64 → $71
Current: $64.34
Upside: +10.35%
Nov 19, 2025
Upgrades: Neutral
Price Target: $81 → $111
Current: $82.92
Upside: +33.86%
Oct 1, 2025
Initiates: Neutral
Price Target: $16
Current: $15.88
Upside: +0.76%
Oct 1, 2025
Initiates: Buy
Price Target: $103
Current: $122.07
Upside: -15.62%
Aug 25, 2025
Initiates: Buy
Price Target: $20
Current: $13.53
Upside: +47.82%
May 6, 2025
Maintains: Neutral
Price Target: $120 → $104
Current: $92.59
Upside: +12.32%
May 1, 2025
Maintains: Buy
Price Target: $13 → $10
Current: $5.85
Upside: +70.94%
Mar 3, 2025
Maintains: Sell
Price Target: $63 → $71
Current: $69.78
Upside: +1.75%
Mar 3, 2025
Maintains: Buy
Price Target: $64 → $55
Current: $63.41
Upside: -13.26%